This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baltch, A. L.
Right arrow Articles by Bopp, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baltch, A. L.
Right arrow Articles by Bopp, L. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 96-104, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.96-104.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Effects of Cytokines and Fluconazole on the Activity of Human Monocytes against Candida albicans

A. L. Baltch,* R. P. Smith, M. A. Franke, W. J. Ritz, P. B. Michelsen, and L. H. Bopp

Stratton Veterans Affairs Medical Center and Albany Medical College, Albany, New York

Received 7 April 2000/Returned for modification 9 June 2000/Accepted 13 October 2000


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

This study evaluates the effects of cytokines, used singly and in combination, on the microbicidal activity of human monocyte-derived macrophages (MDM) against intracellular Candida albicans in the presence and absence of fluconazole. In the absence of fluconazole, the addition of tumor necrosis factor alpha (TNF-alpha ), interleukin-1beta (IL-1beta ), gamma interferon (IFN-gamma ), or IL-4 had no effect on the growth of C. albicans. In contrast, the addition of granulocyte-macrophage colony-stimulating factor (GM-CSF) resulted in decreased growth (P < 0.05), while the addition of IL-10 resulted in increased growth (P < 0.01). In the presence of fluconazole, only the addition of IFN-gamma resulted in an increase in the growth of C. albicans. In the presence or absence of fluconazole, all cytokine combinations except IFN-gamma plus GM-CSF caused significant decreases in growth (P < 0.01). IL-10 and IL-4 did not influence the activity of TNF-alpha or IL-1beta . In the absence or presence of C. albicans the addition of fluconazole, all of the cytokines studied, and combinations of fluconazole and selected cytokines caused increases in nitric oxide (NO) production (P < 0.01). Similar observations were made for superoxide (O2-) only in the presence of C. albicans. The greatest concentrations of NO and O2- were produced when C. albicans alone was present in the assays. Our results demonstrate that in the presence of low concentrations of fluconazole (0.1 times the MIC), selected cytokines and their combinations significantly increase the microbicidal activity of MDM against intracellular C. albicans.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Invasive fungal infections, including disseminated candidiasis, are usually associated with high morbidity and mortality in debilitated and immunocompromised hosts, even when they are receiving appropriate antifungal agents (2, 5, 15, 22, 41). Phagocytic cells, using both oxidative and nonoxidative mechanisms, provide the primary host defense against microbial pathogens, including fungi (2, 8, 12, 13, 30, 32, 59). In addition, cell-mediated immunity and mechanical barriers protect the host. However, chemotherapeutic agents, corticosteroids, and radiation, which are often used in the treatment of malignant disease and AIDS, and for transplantation patients, disrupt these defense mechanisms. If patients are to survive infections associated with neutropenia and other compromises in host defense due to the use of these therapies, it is important to reverse or at least lessen immunosuppression in these patients. By doing so, serious infections such as disseminated candidiasis, which recent reports indicate has a mortality rate of 30 to 95%, may be avoided (5, 7, 22, 61).

Monocytes are an important component of cellular defense mechanisms in humans (8). When stimulated by microbes, monocyte eicosanoid metabolism is altered, arachidonic acid is produced and released, and there is an increase in the production of cytokines, including tumor necrosis factor alpha (TNF-alpha ), interleukin-1beta (IL-1beta ), IL-6, IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferons (8, 9, 11, 27). As a result, chemotaxis and phagocytosis are enhanced (8). The upregulated influx of activated inflammatory cells is an important mechanism by which the host can eliminate invading organisms. During the past decade there has been general agreement that GM-CSF and gamma interferon (IFN-gamma ) enhance the phagocytic function and increase the killing of Candida albicans (43, 48, 49, 52, 63). In addition, GM-CSF increases intracellular oxidative metabolism, as demonstrated by an increase in superoxide (O2-) production (8). A monoclonal antibody against GM-CSF abolishes this effect. Thus, unless monocytes are activated by cytokines such as GM-CSF, their effectiveness in host defense is limited (8, 9). Because GM-CSF and IFN-gamma have been shown to enhance phagocytic function, they are frequently considered for use in patients who are undergoing treatment for malignant disease, who are receiving bone marrow transplants, or who have AIDS (3, 11, 24, 31, 34-37, 40, 58). In addition, cytokines such as IL-1beta , IFN-gamma , and TNF-alpha can stimulate the production of GM-CSF (34). Finally, administration of white blood cells from donors given GM-CSF has been associated with increased survival of neutropenic patients undergoing cancer chemotherapy (1, 14, 36, 37). Although no clearly established recommendations have been published, the use of cytokines as therapeutic adjuvants in the prevention and/or treatment of invasive fungal infections has been advocated (1, 7, 14, 35-37).

The purpose of this study was to define the intracellular interaction between cytokines and subinhibitory concentrations of an antifungal agent, fluconazole, against C. albicans, and to determine which mechanisms are likely to be responsible for the observed candidacidal activity of human monocytes. We studied the anticandidal effects of adding the cytokines TNF-alpha , IL-1beta , IL-4, IL-10, IFN-gamma , and GM-CSF, singly and in combination, to assays with human monocyte-derived macrophages (MDM) in the presence and absence of subinhibitory concentrations of fluconazole. In addition, nitric oxide (NO) and O2- determinations were performed in order to define the oxidative capacity of the activated monocytes.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Microorganism. C. albicans strain T=6, referred to below simply as C. albicans, was originally isolated from the blood of a candidemic patient and was provided by the Wadsworth Laboratories, New York State Department of Health, Albany, N.Y. C. albicans was grown on Sabouraud dextrose agar for 48 h. For opsonization, several colonies were suspended in RPMI 1640 medium (Sigma Chemical Co., St. Louis, Mo.) containing 10% fresh pooled normal human serum and were incubated for 30 min at 37°C. The opsonized cells were then centrifuged and resuspended at a concentration of 2 × 104 CFU/ml in RPMI 1640 medium containing 10% fetal calf serum (FCS).

Antimicrobial agent. Fluconazole was provided by Pfizer Laboratories, Groton, Conn. Antibiotic solutions were made fresh for each experiment in accordance with the supplier's instructions, filter sterilized, and used immediately. The fluconazole MIC for C. albicans, determined according to NCCLS method M27-T, was 1 µg/ml (33).

Preparation of monocytes. MDM were prepared from the heparinized blood of healthy human donors who had signed the informed-consent form approved by the Institutional Review Board of the Albany Medical College and Stratton Veterans Affairs (VA) Medical Center, Albany, N.Y. Mononuclear cells were separated from whole blood by using Histopaque 1077 (Sigma). The resulting mononuclear cell preparation was >= 98% pure. The separated cells were resuspended at a concentration of 2 × 106 cells/ml in RPMI 1640 medium containing 10% FCS, 100 U of penicillin G/ml, and 100 µg of streptomycin/ml. Cell viability, determined by using the trypan blue exclusion test, was >= 98%.

Cytokines. All cytokines were obtained from R & D Systems, Inc., Minneapolis, Minn. TNF-alpha , GM-CSF, and IL-10 were used at a concentration of 100 U/ml. IL-1beta , IFN-gamma , and IL-4 were used at a concentration of 1,000 U/ml.

Study design. Human mononuclear cells (2 × 106) were delivered to the wells of 24-well plates (Corning/Costar Corp., Cambridge, Mass.) in a 1-ml volume and allowed to adhere for 72 h. Monocytes adhered to the wells in a contiguous layer. Medium and nonadherent cells, including lymphocytes, were aspirated from the wells. The adherent monocyte layer was gently washed once with RPMI 1640. TNF-alpha , IL-1beta , IFN-gamma , and GM-CSF were added to duplicate wells singly or in combination, and the monolayers were incubated for 24 h in 5% CO2 at 37°C. In experiments where IL-4 and IL-10 were used, IL-4 and IL-10 were added to cells that had been pretreated with TNF-alpha . These cells were then incubated for an additional 24 h. Opsonized C. albicans (2 × 104 cells in a volume of 1 ml) suspended in RPMI 1640 plus 10% FCS was then added to the wells. One hour was allotted to allow phagocytosis to occur. Nonphagocytosed blastoconidia were removed by aspiration, and the cell layer was washed once with RPMI 1640. Cytokines were readministered to the monolayer, and 0.1 µg of fluconazole (0.1 times the MIC) was then added in a 1-ml volume to each well. Following incubation of the plates at 37°C in an atmosphere containing 5% CO2 for 0, 24, and 48 h, the supernatants were removed, the monocytes were lysed with distilled water, and the lysates were quantitatively plated in duplicate on Sabouraud dextrose agar. The plates were incubated for 24 h at 37°C, and the numbers of surviving organisms were determined. Control wells contained monolayers of monocytes and either C. albicans, fluconazole, C. albicans plus fluconazole, or appropriate cytokines singly or in combination. Each assay was repeated three to six times.

NO and O2- assays. NO concentrations were determined using a nitrate/nitrite colorimetric assay kit (Cayman Chemical, Ann Arbor, Mich.). This assay is based on the enzymatic conversion of nitrate to nitrite by nitrate reductase. Nitrite is detected by the production of a colored product using the Greiss reaction. The concentration is then determined spectrophotometrically. O2- concentrations were determined using the method of Pick and Mizel (42). In this procedure the detection of O2- is based on the reduction of ferricytochrome c and measurement of the increase in absorbance at 550 nm. Each assay was repeated two to eight times.

Statistical methods. For time-kill curves (see Fig. 1 and 2), changes in the numbers of CFU per milliliter from 0 to 24 h, as well as from 0 to 48 h and from 24 to 48 h, were compared among experimental variables. The analysis of variance methodology (53) was applied to the yeast counts following conversion to log10 units. For NO and O2- concentrations (see Table 1 and Fig. 3 to 5), analyses were done at 24 and 48 h using the analysis of variance (53). Contrasts were tested intra-assay. In addition, in Table 1, interassay comparisons were made between live or heat-killed C. albicans and controls. Null hypotheses were specified a priori. The level of significance was 0.05.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Figure 1 shows the effects of TNF-alpha , IL-1beta , IFN-gamma , GM-CSF, IL-4, and IL-10, used singly, in the presence or in the absence of fluconazole, in MDM assays. The numbers of surviving yeasts in MDM treated with TNF-alpha , IL-1beta , IFN-gamma , or IL-4 alone were not significantly different from those in controls at either 24 or 48 h (Fig. 1A, B, C, and E). In contrast, addition of GM-CSF alone (Fig. 1D) resulted in a significant decrease in yeast survival at 24 h (P < 0.05), while addition of IL-10 resulted in an increase in yeast survival (Fig. 1F) (P < 0.01). In the presence of fluconazole, addition of IFN-gamma resulted in an increase in the number of surviving yeasts at 24 h (Fig. 1C) (P < 0.01), and addition of GM-CSF, IL-4, or IL-10 (Fig. 1D through F) caused a decrease in the number of surviving yeasts at 48 h (P < 0.01). Fluconazole had no effect in assays containing TNF-alpha or IL-1 (Fig. 1A and B). In the presence of fluconazole, addition of each of the six cytokines caused a reduction in the growth of the yeast from 24 to 48 h (P < 0.05).


View larger version (16K):
[in this window]
[in a new window]
 
FIG. 1.   Time-kill curves demonstrating in vitro activity of fluconazole (at 0.1 times the MIC) against intracellular C. albicans, with and without cytokines. (A) TNF-alpha (100 U/ml); (B) IL-1beta (1,000 U/ml); (C) IFN-gamma (1,000 U/ml); (D) GM-CSF (100 U/ml); (E) IL-4 (1,000 U/ml); (F) IL-10 (100 U/ml). Solid circles, control; open circles, fluconazole alone; solid inverted triangles, cytokine alone; open inverted triangles, fluconazole plus cytokine.

The results in Fig. 2 demonstrate the effects of combinations of IFN-gamma and GM-CSF, TNF-alpha and IL-10, IL-1beta and IL-10, IL-4 and IL-10, and TNF-alpha , IL-4, and IL-10, in the presence and absence of fluconazole, after 24 and 48 h of incubation. With or without fluconazole, all combinations of cytokines except IFN-gamma plus GM-CSF caused a significant decrease in the growth of C. albicans from 0 to 48 h and from 24 to 48 h. On average, there was significantly less growth than in the controls (P < 0.01). In contrast, no significant differences were observed between the growth of C. albicans in control monolayers and that in monolayers treated with IFN-gamma plus GM-CSF, with or without fluconazole (Fig. 2A). The anti-inflammatory cytokine IL-10 did not negate the activity of proinflammatory cytokines in our assay system, and there was no potentiation of anti-inflammatory cytokine activity when IL-4 and IL-10 were used together (Fig. 2D).


View larger version (20K):
[in this window]
[in a new window]
 
FIG. 2.   Time-kill curves demonstrating in vitro activity of fluconazole (Flu; at 0.1 times the MIC) against intracellular C. albicans, with and without combinations of cytokines. (A) IFN-gamma plus GM-CSF; (B) TNF-alpha and IL-10; (C) IL-1beta and IL-10; (D) IL-4 and IL-10; (E) TNF-alpha , IL-4, and IL-10.

Table 1 shows the NO and O2- concentrations at 0, 24, and 48 h in wells containing MDM in the absence and presence of live or heat-killed C. albicans, with and without fluconazole. At 0 h the concentrations of NO and O2- in wells containing MDM but not C. albicans or fluconazole were very low. Under these conditions, the highest concentrations were reached at 24 h. Treatment of MDM with fluconazole caused an increase in the NO concentration but did not affect the concentration of O2-. In the presence of either live or heat-killed C. albicans and with no fluconazole, NO and O2- concentrations increased dramatically at 24 h (P < 0.01). The greatest increases occurred in the presence of heat-killed C. albicans. In assays containing MDM and either live or heat-killed C. albicans, the NO concentrations at 24 h were 50% lower in the presence of fluconazole than in its absence (P < 0.01). However, the O2- concentration was lower (P < 0.01) in the presence of fluconazole only in the assay containing live C. albicans. At 48 h contrasts remained essentially the same, although in the presence of fluconazole, NO concentrations did not increase as markedly with the addition of C. albicans. O2- concentrations at 48 h were lower (P < 0.01) when fluconazole and heat-killed C. albicans were added to MDM.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 1.   Effects of live and heat-killed C. albicans on the production of nitric oxide and superoxide by MDM

Figures 3 to 5 show the concentrations of NO and O2- in MDM assays at 24 and 48 h in the presence of cytokines (singly), fluconazole, or combinations of cytokines and fluconazole, with and without C. albicans. The average concentrations for controls are also given. In the absence of C. albicans, TNF-alpha , IFN-gamma , GM-CSF, and IL-10 each caused a significant increase in the concentration of NO at both 24 and 48 h (Fig. 3A) (P < 0.01). Fluconazole alone also caused a significant increase at both 24 and 48 h (Fig. 4A). Significant increases in the NO concentration also occurred at 24 and 48 h when fluconazole was combined with either TNF-alpha or IL-10 (Fig. 5A) (P < 0.01). Addition of fluconazole and GM-CSF resulted in an increase in the NO concentration only at 48 h (Fig. 5A) (P < 0.01). With the exception of fluconazole plus IL-10 at 48 h, the concentrations of NO were lower (P < 0.01) in the presence of fluconazole and individual cytokines (Fig. 5A) than they were in the presence of the cytokines alone (Fig. 3A). In contrast to the changes in NO concentrations, no significant changes were observed in O2- concentrations in the absence of C. albicans (Fig. 3B, 4B, and 5B).


View larger version (26K):
[in this window]
[in a new window]
 
FIG. 3.   Concentrations of nitric oxide (A and C) and superoxide (B and D) produced by MDM pretreated with TNF-alpha , GM-CSF, IL-10, or IFN-gamma and either not exposed (A and B) or exposed (C and D) to C. albicans. Asterisks indicate significant differences from controls: * P < 0.05; **, P < 0.01.


View larger version (17K):
[in this window]
[in a new window]
 
FIG. 4.   Concentrations of nitric oxide (A and C) and superoxide (B and D) produced by MDM pretreated with fluconazole (Flu) and either not exposed (A and B) or exposed (C and D) to C. albicans. *, P < 0.05; **, P < 0.01.


View larger version (22K):
[in this window]
[in a new window]
 
FIG. 5.   Concentrations of nitric oxide (A and C) and superoxide (B and D) produced by MDM pretreated with combinations of fluconazole and TNF-alpha , GM-CSF, IL-10, or IFN-gamma , and either not exposed (A and B) or exposed (C and D) to C. albicans. *, P < 0.05; **, P < 0.01.

In MDM assays containing TNF-alpha , IFN-gamma , GM-CSF, IL-10, fluconazole alone, or combinations of the cytokines with fluconazole in the presence of C. albicans, NO concentrations at 24 h were significantly lower (P < 0.01) than those in controls containing only MDM and C. albicans (Fig. 3C, 4C, and 5C). However, except when MDM were treated with GM-CSF plus fluconazole, these same NO concentrations were higher (P < 0.01) than those in control assays containing MDM but not C. albicans (Fig. 3A, 4A, and 5A). At 48 h, fluconazole alone (Fig. 4C) (P < 0.01) and fluconazole plus IL-10 (Fig. 5C) (P < 0.05) caused the NO concentration to decrease, while increases in NO concentrations were observed with the addition of IL-10 alone (Fig. 3C) (P < 0.01) and fluconazole plus GM-CSF (Fig. 5C) (P < 0.05). In contrast to the changes in NO concentrations, O2- concentrations did not change significantly in the presence of cytokines and C. albicans. However, significant decreases in O2- concentrations were observed at both 24 and 48 h in assays containing fluconazole and C. albicans (Fig. 4D) (P < 0.01) and in assays containing IFN-gamma or IL-10, fluconazole, and C. albicans (Fig. 5D) (P < 0.01). In assays containing TNF-alpha or GM-CSF plus fluconazole and C. albicans, the O2- concentrations were lower than those of the controls, although only the differences at 48 h were significant (Fig. 5D) (P < 0.01). In the presence of C. albicans, the addition of individual cytokines or fluconazole combined with either TNF-alpha or GM-CSF caused the O2- concentration to increase at 24 h compared to that in controls containing MDM but not C. albicans (P < 0.01).

Thus, in MDM assays lacking C. albicans but containing cytokines (Fig. 3A), fluconazole (Fig. 4A), or cytokines plus fluconazole (Fig. 5A), NO concentrations were higher than those in controls containing MDM alone. However, in assays containing C. albicans and cytokines, fluconazole, or cytokines plus fluconazole, NO concentrations were significantly lower than those in controls containing only MDM and C. albicans. O2- concentrations were unaffected by cytokines or fluconazole in the absence of C. albicans (Fig. 3B, 4B, and 5B). However, when fluconazole alone (Fig. 4D) or fluconazole and cytokines (Fig. 5D) were present along with C. albicans in MDM assays, O2- concentrations were significantly lower than those in controls containing only MDM and C. albicans.


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Human monocytes and macrophages are important components of host defense against pathogens (7, 8, 18, 61). However, they require activation in order to achieve full antimicrobial activity (8). This activation occurs as a result of exposure to mannan, an important component of the C. albicans cell wall, as well as following exposure to some cytokines (8, 9, 26, 55, 57, 62, 63). The microbicidal activity of monocytes is related to the oxygen burst mechanisms in the cell and may be strain and species dependent (8, 10, 12, 17, 19, 23, 29, 30, 59, 61). Fluconazole is a fungistatic triazole drug that inhibits the formation of C. albicans hyphae and is concentrated in human phagocytes (1, 2, 51, 56). Fluconazole interferes with 14-alpha demethylation of sterols, resulting in the accumulation of 14-alpha -methylated sterols in the cell membrane. C. albicans cells with 14-alpha -demethylated sterols are especially vulnerable to the oxygen-dependent microbicidal activity of phagocytes in which the initial oxygen product is O2- (51). Furthermore, the inability of the 14-alpha -demethylation-deficient cells to form hyphae may allow the fungus to be more easily ingested by phagocytes (51).

It has been clearly demonstrated in a murine model of disseminated candidiasis that certain cytokines produced by monocytes, for example TNF-alpha , increase survival (4, 6, 27, 28). Furthermore, the use of GM-CSF in the treatment of neutropenic cancer patients with systemic, invasive fungal infections has been shown to improve patient survival (14, 16, 18, 21, 34-37, 40, 43, 44, 48, 49, 61). Our study was undertaken in order to define the activities of six cytokines used singly and in combination, in the presence and absence of fluconazole, in a human MDM assay against a fluconazole-sensitive C. albicans strain. In addition to evaluation of the importance of cytokines in candidacidal activity, the mechanism of this activity was evaluated by determining the O2- and NO concentrations in cells following exposure to cytokines and fluconazole in the presence and absence of C. albicans.

Our results demonstrate that in the presence or absence of fluconazole, TNF-alpha and IL-1beta had no effect on the microbicidal activity of the monocytes. In contrast, while IFN-gamma had no effect on the intracellular killing of the yeast in the absence of fluconazole, in the presence of fluconazole IFN-gamma stimulated intracellular killing at 24 h (P < 0.01). GM-CSF increased microbicidal activity at 24 h in the absence of fluconazole (P < 0.05). In addition, GM-CSF increased the candidacidal activity of MDM in the presence of fluconazole at 48 h (P < 0.01). Similar observations with GM-CSF at 24 h have been described previously, although the assay procedures described differed from ours (20, 31). Of interest was our observation that without fluconazole, microbicidal activity was lower at 24 h in the presence of IL-10 than in the controls (P < 0.01) but that at 48 h the presence of IL-10 was associated with increased microbicidal action (P < 0.01) in both the presence and the absence of fluconazole. Suppression of the microbicidal effect of macrophages by IL-4 and IL-10 in the absence of fluconazole has been described previously (25, 38, 46, 47, 54, 60, 61). We observed a 13-fold increase in NO concentration in the presence of MDM exposed to live C. albicans. In addition, we demonstrated that the NO concentrations in assays that included cytokines and/or fluconazole along with C. albicans were low compared to the NO concentrations in assays containing only MDM and C. albicans. Combinations of GM-CSF plus IFN-gamma had no effect on microbicidal activity, regardless of the presence or absence of fluconazole. In contrast, combinations of TNF-alpha plus IL-10, IL-1beta plus IL-10, IL-4 plus IL-10, and TNF-alpha plus IL-4 and IL-10 were associated with significantly increased microbicidal activity at 48 h and from 24 to 48 h (P < 0.01) in the absence or presence of fluconazole. In contrast to TNF-alpha , IL-1beta , and IFN-gamma , GM-CSF, IL-4, and IL-10 increased the microbicidal activity of MDM in the presence of fluconazole. Since this effect was significantly greater when fluconazole was present in the assay, our data support the use of selected cytokines when fluconazole is used for the therapy of disseminated candidiasis.

In this study we assessed the production of NO and O2- by MDM activated by cytokines alone, fluconazole alone, C. albicans alone, and combinations of these. The roles of NO and O2- during infection are complex. In contrast to the observations of Schneeman et al. (50), we detected NO production by MDM that had been stimulated by cytokines, fluconazole, and combinations of cytokines and fluconazole (Table 1; Fig. 3 to 5). The regulation of NO production by cytokines and the effect it has on the microbicidal activity of monocytes remain incompletely understood (12, 30). It is known, however, that NO production is enhanced in macrophages stimulated with TNF-alpha , IFN-gamma , IL-1, and IL-2 (10, 23, 29, 32). We demonstrated increased NO production by MDM stimulated with TNF-alpha and IFN-gamma , as well as by MDM stimulated with GM-CSF. Although previous observations indicate that IL-4 and IL-10 do not induce NO synthetase production (29, 30), IL-10 stimulated NO production by MDM in our assays. Macrophages exposed to pathogens causing mycobacterial infections, malaria, viral hepatitis, and AIDS show enhanced NO production (12). NO and its derivatives are important as antimicrobial effectors, with activity against parasitic, fungal, bacterial, and viral infection (12, 30). Evidence for the elaboration by C. albicans of a soluble factor inhibiting NO production has recently been described (10). Similarly to NO, O2- production by MDM was greatly enhanced by exposure to live C. albicans. Although cytokines alone did not affect O2- production by MDM exposed to live C. albicans (Fig. 3D), the presence of fluconazole or fluconazole plus cytokines resulted in a reduction in O2- concentrations in MDM assays containing C. albicans (Fig. 4D and 5D).

In our assays there was no clear correlation between NO and O2- production and intracellular killing of C. albicans by human monocytes. The fact that maximum production of NO and O2- occurred when monocytes were exposed to C. albicans alone and that NO and O2- production were suppressed in monocytes exposed to C. albicans in the presence of cytokines and/or fluconazole emphasizes the complexity of the interaction of C. albicans with host macrophages.

The results described in our study clearly indicate that the microbicidal activity of human monocytes is closely associated with the activities of selected cytokines. Furthermore, subinhibitory concentrations of fluconazole increase these cytokine-specific effects against fluconazole-sensitive intracellular C. albicans. These results support the use of selected cytokines as adjunctive therapy in disseminated candidiasis. However, the mechanism by which cytokines and fluconazole enhance intracellular killing of C. albicans by human monocytes warrants further investigation.


    ACKNOWLEDGMENTS

This work was supported by Pfizer Laboratories and in part by the Veterans Affairs Research Service.


    FOOTNOTES

* Corresponding author. Mailing address: Infectious Disease Research, Stratton VA Medical Center, Albany, NY 12208. Phone: (518) 462-3311, ext. 3080. Fax: (518) 462-3350. E-mail: BALTCH.ALDONA_{at}ALBANY.VA.GOV.


    REFERENCES
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

1. Anaissie, E. J. 1998. Immunodulation in the treatment of invasive fungal infections: present and future directions. Clin. Infect. Dis. 26:1264-1265[Medline].
2. Andriole, V. T. 1999. Current and future antifungal therapy: new targets for antifungal agents. J. Antimicrob. Chemother. 44:151-162[Abstract/Free Full Text].
3. Atkinson, K., J. C. Biggs, K. Downs, C. Juttner, K. Bradstock, R. M. Lowenthal, B. Dale, and J. Szer. 1991. GM-CSF after allogeneic bone marrow transplantation: accelerated recovery of neutrophils, monocytes and lymphocytes. Aust. NZ J. Med. 21:686-692[Medline].
4. Aybay, C., and T. Imir. 1996. Tumor necrosis factor (TNF) induction from monocyte/macrophages by Candida species. Immunobiology 196:363-374[Medline].
5. Beck-Sague, C. M., and W. Jarvis. 1993. National nosocomial infections surveillance system. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J. Infect. Dis. 167:1247-1251[Medline].
6. Blasi, E., L. Pitzurra, M. Puliti, R. Mazzolla, R. Barluzzi, S. Saleppico, and F. Bistoni. 1994. Different events involved in the induction of macrophage tumor necrosis factor by Candida albicans and lipopolysaccharide. Cell. Immunol. 157:501-509[CrossRef][Medline].
7. Bodey, G. P. 1993. What's new in fungal infection in leukemic patients. Leukem. Lymph. 11(Suppl. 2):S127-S135.
8. Calderone, R., and J. Sturtevant. 1994. Macrophage interactions with Candida. Immunol. Ser. 60:505-515[Medline].
9. Castro, M., J. A. Bjoraker, M. S. Rohrbach, and A. H. Limper. 1996. Candida albicans induces the release of inflammatory mediators from human peripheral blood monocytes. Inflammation 20:107-122[CrossRef][Medline].
10. Chinen, T., M. H. Qureshi, Y. Koguchi, and K. Kawakami. 1999. Candida albicans suppresses nitric oxide (NO) production by interferon-gamma (IFN-gamma )- and lipopolysaccharide (LPS)-stimulated murine peritoneal macrophages. Clin. Exp. Immunol. 115:491-497[CrossRef][Medline].
11. Coffey, M. J., S. M. Phare, S. Cinti, M. Peters-Golden, and P. H. Kazanjian. 1999. Granulocyte-macrophage colony-stimulating factor upregulates reduced 5-lipoxygenase metabolism in peripheral blood monocytes and neutrophils in acquired immunodeficiency syndrome. Blood 94:3897-3905[Abstract/Free Full Text].
12. DeGroote, M. A., and F. C. Fang. 1999. Antimicrobial properties of nitric oxide, p. 231-264. In F. C. Fang (ed.), Nitric oxide and infection. Kluwer Academic/Plenum Publishers, New York, N.Y.
13. Diamond, R. D., E. Huber, and C. C. Haudenschild. 1983. Mechanisms of destruction of Aspergillus fumigatus hyphae mediated by human monocytes. J. Infect. Dis. 147:474-483[Medline].
14. Dignani, M. C., E. J. Anaissie, J. P. Hester, S. O'Brien, S. E. Vartivarian, J. H. Rex, H. Kantarjian, D. B. Jendiroba, B. Lichtiger, B. S. Andersson, and E. J. Freireich. 1997. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 11:1621-1630[CrossRef][Medline].
15. Fridkin, S. K., and W. R. Jarvis. 1996. Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev. 9:499-511[Abstract].
16. Futenma, M., K. Kawakami, and A. Saito. 1995. Production of tumor necrosis factor-alpha in granulocytopenic mice with pulmonary candidiasis and its modification with granulocyte colony-stimulating factor. Microbiol. Immunol. 39:411-417[Medline].
17. Garcha, U. K., E. Brummer, and D. A. Stevens. 1995. Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species. J. Infect. Dis. 172:1620-1623[Medline].
18. Giles, F. J. 1998. Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants. Clin. Infect. Dis. 26:1282-1289[Medline].
19. Ghezzi, M. C., G. Raponi, S. Angeletti, and C. Mancini. 1998. Serum-mediated enhancement of TNF-alpha release by human monocytes stimulated with the yeast form of Candida albicans. J. Infect. Dis. 178:1743-1749[CrossRef][Medline].
20. Gujral, S., E. Brummer, and D. A. Stevens. 1996. Role of extended culture time on synergy of fluconazole and human monocyte-derived macrophages in clearing Candida albicans. J. Infect. Dis. 174:888-890[Medline].
21. Jones, T. C. 1994. Future uses of granulocyte-macrophage colony-stimulating factor (GM-CSF). Stem Cells 12(Suppl. 1):S229-S240.
22. Kao, A. S., M. E. Brandt, W. R. Pruitt, L. A. Conn, B. A. Perkins, D. S. Stephens, W. S. Baughman, A. L. Reingold, G. A. Rothrock, M. A. Pfaller, R. W. Pinner, and R. A. Hajjeh. 1999. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1164-1170[CrossRef][Medline].
23. Koshland, D. E. 1992. The molecule of the year. Science 258:1861[Free Full Text].
24. Kullberg, B. J., J. W. van't Wout, R. J. M. Poell, and R. van Furth. 1992. Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice. Antimicrob. Agents Chemother. 36:1225-1229[Abstract/Free Full Text].
25. Levitz, S. M., A. Tabuni, S. Nong, and D. T. Golenbock. 1996. Effects of interleukin-10 on human peripheral blood mononuclear cell responses to Cryptococcus neoformans, Candida albicans, and lipopolysaccharide. Infect. Immun. 64:945-951[Abstract].
26. Li, S. P., S. Lee, and J. E. Domer. 1998. Alterations in frequency of interleukin-2 (IL-2)-, gamma interferon-, or IL-4-secreting splenocytes induced by Candida albicans mannan and/or monophosphoryl lipid A. Infect. Immun. 66:1392-1399[Abstract/Free Full Text].
27. Louie, A., A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, J. K. Singh, and M. Gordon. 1995. Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of disseminated candidiasis. J. Infect. Dis. 171:406-415[Medline].
28. Louie, A., A. L. Baltch, R. P. Smith, M. Franke, W. Ritz, J. Singh, and M. A. Gordon. 1994. Tumor necrosis factor has a protective effect in a murine model of systemic candidiasis. Infect. Immun. 62:2761-2772[Abstract/Free Full Text].
29. Moncada, S., R. M. J. Palmer, and E. A. Higgs. 1991. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43:109-142[Medline].
30. Mühl, H., and C. Dinarello. 1999. Cytokine regulation of nitric oxide production, p. 77-94. In F. C. Fang (ed.), Nitric oxide and infection. Kluwer Academic/Plenum Publishers, New York, N.Y.
31. Natarajan, U., N. Randhawa, E. Brummer, and D. A. Stevens. 1998. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophage and synergy with fluconazole. J. Med. Microbiol. 47:359-363[Abstract/Free Full Text].
32. Nathan, C. F. 1989. Respiratory burst in adherent human neutrophils: triggering by colony-stimulating factors CSF-GM and CSF-G. Blood 73:301-306[Abstract/Free Full Text].
33. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing for yeasts. Approved standard M27-T. National Committee for Clinical Laboratory Standards, Wayne, Pa.
34. Nemunaitis, J. 1997. A comparative review of colony-stimulating factors. Drugs 54:709-729[Medline].
35. Nemunaitis, J. 1998. Use of macrophage colony-stimulating factor in the treatment of fungal infections. Clin. Infect. Dis. 26:1279-1281[Medline].
36. Nemunaitis, J., C. D. Buckner, K. S. Dorsey, D. Willis, W. Meyer, and F. Appelbaum. 1998. Retrospective analysis of infectious disease in patients who received recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiving a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer. Am. J. Clin. Oncol. 21:341-346[CrossRef][Medline].
37. Nemunaitis, J., K. Shannon-Dorcy, F. R. Appelbaum, J. Meyers, A. Owens, R. Day, D. Ando, C. O'Neill, D. Buckner, and J. Singer. 1993. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 82:1422-1427[Abstract/Free Full Text].
38. Opal, S. M., J. C. Wherry, and P. Grint. 1998. Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Clin. Infect. Dis. 27:1497-1507[Medline].
39. Pascual, A., I. Garcia, C. Conejo, and E. J. Perea. 1993. Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother. 37:187-190[Abstract/Free Full Text].
40. Peters, B. G., D. R. Adkins, B. R. Harrison, W. S. Velasquez, F. R. Dunphy, P. J. Petruska, C. E. Bowers, R. Niemeyer, W. McIntyre, D. Vrahnos, S. E. Auberry, and G. Spitzer. 1996. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Bone Marrow Transplant. 18:93-102[Medline].
41. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22(Suppl.):S89-S94.
42. Pick, E., and D. Mizel. 1981. Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader. J. Immunol. Methods 46:211-226[CrossRef][Medline].
43. Polonelli, L., and A. Cassone. 1999. Novel strategies for treating candidiasis. Curr. Opin. Infect. Dis. 12:61-66.
44. Poynton, C. H. 1990. Interferon gamma  and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin. Infect. Dis. 26:1270-1278.
45. Rodriguez-Adrian, L. J., M. L. Grazziutti, J. H. Rex, and E. J. Anaissie. 1998. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin. Infect. Dis. 26:1270-1278[Medline].
46. Roilides, E., I. Kadiltsoglou, A. Dimitriadou, M. Hatzistilianou, A. Manitsa, J. Karpouzas, P. A. Pizzo, and T. J. Walsh. 1997. Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with decreased uptake of blastoconidia. FEMS Immunol. Med. Microbiol. 19:169-180[CrossRef][Medline].
47. Roilides, E., A. Anastasio-Katsiardani, A. Dimitriadou-Georgiadou, I. Kadiltsoglou, S. Tsaparidou, C. Pantelliadis, and T. J. Walsh. 1998. Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus. J. Infect. Dis. 178:1734-1742[CrossRef][Medline].
48. Rowe, J. M., J. W. Andersen, J. J. Mazza, J. M. Bennett, E. Paietta, F. A. Hayes, D. Oette, P. A. Cassileth, E. A. Stadtmauer, and P. H. Wiernik. 1995. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457-462[Abstract/Free Full Text].
49. Rowe, J. M. 1998. Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clin. Infect. Dis. 26:1290-1294[Medline].
50. Schneemann, M., G. Schoedon, S. Hofer, N. Blau, L. Guerrero, and A. Schaffner. 1993. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J. Infect. Dis. 167:1358-1363[Medline].
51. Shimokawa, O., and H. Nakayama. 1992. Increased sensitivity of Candida albicans cells accumulating 14alpha -methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents. Antimicrob. Agents Chemother. 36:1626-1629[Abstract/Free Full Text].
52. Smith, P. D., C. L. Lamerson, S. M. Banks, S. S. Saini, L. M. Wahl, R. A. Calderone, and S. M. Wahl. 1990. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J. Infect. Dis. 161:999-1005[Medline].
53. Stuart, A., and J. K. Ord. 1991. Kendall's advanced theory of statistics, vol. 2. , p. 1101-1153. Oxford University Press, New York, N.Y.
54. Tonnetti, L., R. Spaccapelo, E. Cenci, A. Mencacci, P. Puccetti, R. L. Coffman, F. Bistoni, and L. Romani. 1995. Interleukin-4 and -10 exacerbate candidiasis in mice. Eur. J. Immunol. 25:1559-1565[Medline].
55. Torosantucci, A., P. Chiani, I. Quinti, C. M. Ausiello, I. Mezzaroma, and A. Cassone. 1997. Responsiveness of human polymorphonuclear cells (PMNL) to stimulation by a mannoprotein fraction (MP-F2) of Candida albicans; enhanced production of IL-6 and tumour necrosis factor-alpha (TNF-alpha ) by MP-F2-stimulated PMNL from HIV-infected subjects. Clin. Exp. Immunol. 107:451-457[CrossRef][Medline].
56. Van't Wout, J. W., I. Meynaar, I. Linde, R. Poell, H. Mattie, and R. Van Furth. 1990. Effect of amphotericin B, fluconazole and itraconazole on intracellular Candida albicans and germ tube development in macrophages. J. Antimicrob. Chemother. 25:803-811[Abstract/Free Full Text].
57. Vazquez, N., H. R. Buckley, and T. J. Rogers. 1996. Production of IL-6 and TNF-alpha by the macrophage-like cell line RAW 264.7 after treatment with a cell wall extract of Candida albicans. J. Interferon Cytokine Res. 16:465-470[Medline].
58. Vazquez, J. A., S. Gupta, and A. Villaneuva. 1998. Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur. J. Clin. Microbiol. Infect. Dis. 17:781-783[CrossRef][Medline].
59. Vazquez-Torres, A., J. Jones-Carson, T. Warner, and E. Balish. 1995. Nitric oxide enhances resistance of SCID mice to mucosal candidiasis. J. Infect. Dis. 172:192-198[Medline].
60. Vonk, A. G., M. G. Netea, N. E. J. Denecker, I. C. M. M. Verschueren, J. W. M. van der Meer, and B. J. Kullberg. 1998. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. J. Antimicrob. Chemother. 42:469-474[Abstract/Free Full Text].
61. Walsh, T. J., J. W. Hiemenz, and E. Anaissie. 1996. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect. Dis. Clin. N. Am. 10:365-400[CrossRef][Medline].
62. Wang, Y., S. P. Li, S. A. Moser, K. L. Bost, and J. E. Domer. 1998. Cytokine involvement in immunomodulatory activity affected by Candida albicans mannan. Infect. Immun. 66:1384-1391[Abstract/Free Full Text].
63. Yamamoto, Y., T. W. Klein, M. Tomioka, and H. Friedman. 1997. Differential effects of granulocyte/macrophage colony-stimulating factor (GM-CSF) in enhancing macrophage resistance to Legionella pneumophila vs. Candida albicans. Cell. Immunol. 176:75-81[CrossRef][Medline].


Antimicrobial Agents and Chemotherapy, January 2001, p. 96-104, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.96-104.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Baltch, A. L., Bopp, L. H., Smith, R. P., Ritz, W. J., Michelsen, P. B. (2008). Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. J Antimicrob Chemother 62: 1285-1290 [Abstract] [Full Text]  
  • Bopp, L. H., Baltch, A. L., Ritz, W. J., Michelsen, P. B., Smith, R. P. (2006). Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages.. J Med Microbiol 55: 865-870 [Abstract] [Full Text]  
  • Patera, A. C., Menzel, F., Jackson, C., Brieland, J. K., Halpern, J., Hare, R., Cacciapuoti, A., Loebenberg, D. (2004). Effect of Granulocyte Colony-Stimulating Factor Combination Therapy on Efficacy of Posaconazole (SCH56592) in an Inhalation Model of Murine Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 48: 3154-3158 [Abstract] [Full Text]  
  • Marcil, A., Harcus, D., Thomas, D. Y., Whiteway, M. (2002). Candida albicans Killing by RAW 264.7 Mouse Macrophage Cells: Effects of Candida Genotype, Infection Ratios, and Gamma Interferon Treatment. Infect. Immun. 70: 6319-6329 [Abstract] [Full Text]  
  • Coste, A., Linas, M. D., Cassaing, S., Bernad, J., Chalmeton, S., Seguela, J. P., Pipy, B. (2002). A sub-inhibitory concentration of amphotericin B enhances candidastatic activity of interferon-{gamma}- and interleukin-13-treated murine peritoneal macrophages. J Antimicrob Chemother 49: 731-740 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baltch, A. L.
Right arrow Articles by Bopp, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baltch, A. L.
Right arrow Articles by Bopp, L. H.